Pharmaceutical and biological preparations for the treatment of hereditary angioedema (HAE); Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation

'agent':58 'angioedema':10,21,28 'attack':56 'biolog':3,14,32 'bradykinin':80 'caus':25 'complic':24 'control':79 'crispr/cas9':63 'diseas':45 'disord':42 'edit':36 'gene':35,48,71 'generat':81 'genet':44 'guid':66 'hae':11,22,29 'hereditari':9,20,27 'inject':47 'intraven':46 'klkb1':70 'manag':19,54 'name':34 'natur':61 'pharmaceut':1,12,30 'plasma':76 'prekallikrein':77 'prepar':4,15,33,37,50 'product':74 'protein':41,64 'reduc':73 'rnas':67 'swell':55 'target':68 'therapeut':57 'therapi':49 'treat':17,52 'treatment':7 'use':39

LONQURJA

Owners

Goods & Services